BJP Mental Health Guidelines from NICE
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coppen, A.
Right arrow Articles by Peet, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coppen, A.
Right arrow Articles by Peet, M.

The British Journal of Psychiatry 133: 206-210 (1978)
© 1978 The Royal College of Psychiatrists

Mianserin and lithium in the prophylaxis of depression

A Coppen, K Ghose, R Rao, J Bailey and M Peet

Forty-one out-patients with a history of at least three attacks of depressive illness were randomly allocated to treatment on a double- blind basis for one year with either mianserin 20 mg three times daily plus placebo lithium tablets, or to lithium tablets once daily plus placebo mianserin tablets. After one year, the dosage of mianserin was increased to 30 mg t.d.s. for a further six months. All but three of the patients had previously been stabilized on prophylactic lithium therapy. Lithium was found to be significantly superior to mianserin in avoiding admission to hospital or ECT. The overall affective morbidity index, calculated from global rating, showed no significant difference between drugs, but the index of the mianserin group was higher in the second six months than in the first. The lithium group showed no such change. Lithium remains the choice for the prophylaxis of unipolar recurrent depressive illness.


This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
A. Cipriani, H. Pretty, K. Hawton, and J. R. Geddes
Lithium in the Prevention of Suicidal Behavior and All-Cause Mortality in Patients With Mood Disorders: A Systematic Review of Randomized Trials
Am J Psychiatry, October 1, 2005; 162(10): 1805 - 1819.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
E S Paykel
Continuation and maintenance therapy in depression
Br. Med. Bull., March 1, 2001; 57(1): 145 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. M. Kane, F. M. Quitkin, A. Rifkin, J. R. Ramos-Lorenzi, D. D. Nayak, and A. Howard
Lithium Carbonate and Imipramine in the Prophylaxis of Unipolar and Bipolar II Illness: A Prospective, Placebo-Controlled Comparison
Arch Gen Psychiatry, September 1, 1982; 39(9): 1065 - 1069.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1978 The Royal College of Psychiatrists.